
First GLP-1 gene therapy gets green light for diabetes trial
Fractyl Health has received Clinical Trial Application authorisation in the Netherlands to initiate the Phase I/II first-in-human study of RJVA-001, the first clinical candidate from the company’s Rejuva Smart GLP-1 gene therapy platform. With this authorisation, Fractyl believes RJVA-001 is the first adeno-associated virus (AAV)-based gene therapy… Read More















